By Emilie Ruscoe ( March 15, 2022, 9:01 PM EDT) -- Kidney drug company Akebia Therapeutics Inc. is facing a shareholder suit that accuses it of misrepresenting the regulatory approval chances for an anemia therapy it had in the works, which an investor said pushed down trading prices for the company's shares by nearly 75%....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.